Single-centre experience of 85 patients with a continuous-flow left ventricular assist device: clinical practice and outcome after extended support

Abstract

In view of the increasing shortage of donor hearts, HM II LVAD support may be considered a life-saving treatment in end-stage HF patients, with good survival. However, it is still associated with some serious adverse events, of which neurological complications are the most critical.